After back-to-back years of 20%-plus gains in 2023 and 2024, the S&P 500 is off to another strong start to 2025. However, the S&P 500's forward earnings multiple of 22 (as of Feb. 7) was also ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with two PharmaLex experts about navigating complex R&D ...

Angels for Change (A4C) announces the pilot launch of Project GOLD (Generic Oncology Lifesaving Drugs), a new resiliency ...

Nearly 200 medications, including several oncology treatments, are now available through the program.

The Trump administration’s moves to trim government spending pose a short-term “understated risk” for companies all across ...

Headquartered in Conshohocken, Pennsylvania, Cencora, Inc. (COR) is a leading pharmaceutical services company dedicated to ...

Shares of Cencora Inc. COR shed 1.28% to $243.59 Wednesday, on what proved to be an all-around grim trading session for the ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

Leerink Partnrs dropped their Q2 2025 EPS estimates for Cencora in a report released on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $4.08 per ...